Investor Presentation
Commercialisation Strategy
US Lung Diagnostic
Market Opportunity
•
•
.
.
4DMedical's initial core focus is the rapid penetration of
the US market.
FDA Clearance of XV LVAS product allows 4DMedical to
market for a wide range of applications and an
experienced in-house sales force has already been
recruited.
XV LVAS provides a cost-effective and rapid path to
market, while SaaS platform allows for ability to scale up
quickly.
Market strategy to target large hospitals operating at
scale to drive take up and market adoption
Department of Veterans Affairs (VA) is US largest
healthcare provider and directly funds costs (no
requirement for reimbursement)
Clinical trial partner hospitals present high value
revenue opportunity with existing presence and
acceptance of technology
Given the large market size, even low market penetration
could see substantial revenue generation with high gross
margin
73 million respiratory diagnostic tests undertaken each
year in the US
✓ 6,176 hospitals, each with an average of ~150 hospital
beds
4DMedical's initial target hospitals average ~500
hospital beds
✓ 2% of US lung diagnostic market represents ~US$250M
revenue per annum
Thoracic X-ray
Thoracic CT
scans
PFT
Nuclear
Medicine
Total
US Procedures
49,590,000
10,888,664
12,200,000
778,000
73,456,664
US Spend (US$) $5.95 billion
$5.76 billon $878 million $1.17 billion $13.76 billion
% share of US Lung
diagnostic procedures
Ave. price per
Diagnostic (US$)
4DMedical Revenue
Opportunity @
2% Market Share,
US$175/scan
66.9%
14.7%
16.5%
1.1%
99.2%
$120
$525
$50-$2,500
$1,503
$50-$2,500
US$173.56m
US$38.12m US$42.70m
US$2.72m
$257.10m
Pg 26 | Investor presentation
4DMedicalView entire presentation